1. Home
  2. ONL vs SGMT Comparison

ONL vs SGMT Comparison

Compare ONL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.75

Market Cap

165.4M

Sector

Real Estate

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.37

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
SGMT
Founded
2021
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
165.4M
169.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ONL
SGMT
Price
$2.75
$7.37
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$3.00
$26.13
AVG Volume (30 Days)
627.1K
1.3M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
2.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$147,647,000.00
$2,000,000.00
Revenue This Year
$4.10
N/A
Revenue Next Year
$3.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$4.50
52 Week High
$3.04
$11.41

Technical Indicators

Market Signals
Indicator
ONL
SGMT
Relative Strength Index (RSI) 44.45 54.97
Support Level $2.62 $7.09
Resistance Level $2.98 $7.95
Average True Range (ATR) 0.11 0.45
MACD -0.01 0.03
Stochastic Oscillator 40.26 57.48

Price Performance

Historical Comparison
ONL
SGMT

About ONL Orion Office REIT Inc.

Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: